Drug Profile

COVID-19 vaccine - EnGeneIC

Alternative Names: Corona virus vaccine; COVID-19-EDV

Latest Information Update: 08 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EnGeneIC
Class COVID-19 vaccines; Viral vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued COVID 2019 infections

Most Recent Events

08 Jan 2025 Discontinued - Phase-I for COVID-2019 infections (In volunteers) in Australia (unspecified route) (EnGeneIC pipeline, January 2025; ImmunityBio pipeline, January 2025)
28 Oct 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Australia
28 Jun 2022 EnGeneIC plans clinical trials for COVID-2019 infections in Australia in July-August 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com